Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Luminari

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
The Lancet. Haematology|May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumoursCristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
Leukemia & Lymphoma|March 8, 2017
Report of the 6th International Workshop on PET in lymphomaCristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Leukemia & Lymphoma|February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphomaEmmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Hematological Oncology|June 22, 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)Annarita Conconi, Andrea Janikova, Barbara Vannata, et al.
Blood Advances|June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphomaAnnalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
End of induction [<sup>18</sup>F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trialLuca Guerra, Stephane Chauvie, Federico Fallanca, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
The Lancet. Haematology|May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumoursCristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
Leukemia & Lymphoma|March 8, 2017
Report of the 6th International Workshop on PET in lymphomaCristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Leukemia & Lymphoma|February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphomaEmmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Hematological Oncology|June 22, 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)Annarita Conconi, Andrea Janikova, Barbara Vannata, et al.
Blood Advances|June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphomaAnnalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
End of induction [<sup>18</sup>F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trialLuca Guerra, Stephane Chauvie, Federico Fallanca, et al.
Pageof 21